- You’ve tried therapy.
- You’ve tried medication.
- You’ve given it time.
- And yet, something still feels heavy.
For many individuals struggling with depression, anxiety, mood instability, or persistent symptoms, the path to feeling better is not always linear. When traditional antidepressants or therapy alone haven’t provided enough relief, it does not mean you have failed treatment. It may mean your brain needs a different approach.
At
Blue Umbrella Psychiatry, we now offer
ketamine therapy in three forms: IV, IM, and in-clinic oral administration, allowing for personalized care based on clinical needs and patient comfort.
What Is Ketamine Therapy?
Ketamine has been used safely in medical settings for decades. In psychiatric care, it has gained attention for its potential to support individuals experiencing:
- Treatment-resistant depression
- Persistent depressive symptoms
- Suicidal thoughts
- Mood disorders
- Severe anxiety
- PTSD
Unlike traditional antidepressants that primarily target serotonin, ketamine works on the glutamate system, specifically NMDA receptors. Glutamate is the brain’s most abundant excitatory neurotransmitter and plays a key role in neural communication and plasticity.
By modulating this system, ketamine may support the brain’s ability to form new neural connections. For some individuals, this can translate into symptom relief when other treatments have not been sufficient.
Ketamine Options at Blue Umbrella Psychiatry
We recognize that treatment should be individualized. That is why we offer three administration methods:
IV Ketamine
- 90-minute medically monitored infusion
- Precise dosing and controlled delivery
- Structured clinical environment
IM Ketamine
- 90-minute monitored session
- Administered intramuscularly
- Calm, supervised setting
In-Clinic Oral Ketamine
- 60-minute monitored session
- Lower-intensity administration option
- Comfortable, supportive environment
All ketamine sessions include time in our
Breakthrough Lounge — a dedicated space designed for decompression and transition after treatment. Patients can relax, wait for their ride safely, and connect with others who are navigating similar healing journeys. The goal is to create not only a clinical experience, but a supportive one.
Important Considerations
Ketamine for depression and mood disorders is considered off-label use, meaning it is not FDA-approved specifically for depression in its racemic form.
Treatment at Blue Umbrella Psychiatry is:
- Fully self-pay
- Transparent in pricing
- Provided after comprehensive psychiatric evaluation
- Not guaranteed to produce specific outcomes
Candidacy is determined carefully to ensure safety and appropriateness.
Who Might Consider Ketamine Therapy?
Ketamine therapy may be appropriate for individuals who:
- Have not responded adequately to traditional antidepressants
- Continue to experience persistent depressive symptoms
- Feel emotionally stuck despite ongoing treatment
- Are seeking a different neurobiological pathway
It is not the right choice for everyone, but for some patients, it can be a meaningful addition to a comprehensive mental health plan.
Integrating Ketamine with Ongoing Care
Ketamine therapy is most effective when integrated into a broader treatment strategy. Many patients continue:
- Individual therapy
- Medication management
- Lifestyle and wellness interventions
At Blue Umbrella Psychiatry, we approach care collaboratively and intentionally. Ketamine is not a replacement for therapy — it is a potential tool within a personalized treatment plan.
A Different Path Forward
If you feel like you have done everything “right” and still are not experiencing the relief you hoped for, it may be time to explore additional options.
- A different mechanism.
- A different pathway.
- A different approach.
Take Action:
If you would like to learn whether IV, IM, or oral ketamine therapy may be appropriate for you, schedule a consultation with our team at
Blue Umbrella Psychiatry. We are here to provide thoughtful, evidence-informed care and support your long-term mental wellness.
